{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-23-000062","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.477992+00:00","generated_at":"2026-06-07T14:51:49.349866+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nurix reports positive Phase 1 data for BTK degraders NX-5948 and NX-2127 at ASH 2023","bullets":["NX-5948: 3 partial responses in CLL (n=7); no DLTs or treatment-related SAEs across 50-450 mg doses.","NX-2127: 2 complete responses in NHL (MCL, DLBCL); 40.7% ORR in CLL (n=27), up from 33% at ASH 2022.","NX-2127 safety manageable: neutropenia dose-related, atrial fibrillation 11.1% (down from 17% prior).","Dose escalation continues for both programs; more data expected in 2024.","Company plans to develop NX-5948 broadly in CLL and other NHL indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-23-000062","json":"https://secwatch.observer/filing/0001549595-23-000062.json","markdown":"https://secwatch.observer/filing/0001549595-23-000062.md","text":"https://secwatch.observer/filing/0001549595-23-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000062/0001549595-23-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959523000062/nrix-20231211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:51:49.349866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}